Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastrointest Pathophysiol. Nov 15, 2014; 5(4): 405-415
Published online Nov 15, 2014. doi: 10.4291/wjgp.v5.i4.405
Published online Nov 15, 2014. doi: 10.4291/wjgp.v5.i4.405
Definition | Example | |
Class I drug | Ia: at least one case report, evidence of a positive re-challenge, and exclusion of other causes of AP | Codeine, cytarabine, dapsone, enalapril, furosemide, isoniazid, mesalamine, metronidazole, pentamidine, pravastatin, procainamide, simvastatin, sulfamethoxazole, sulindac, tetracycline, valproic acid |
Ib: similar to class Ia, except that other causes of AP could not be ruled out | Amiodarone, azathioprine, dexamethasone, ifosfaide, lamivudine, losartan, 6-MP, premarin, TMP-SMZ | |
Class II drugs | Include at least four case reports with a consistent latency period for at least 75% of the cases | Acetaminophen, Clozapine, DDI, erythromycin, estrogen, l-asparaginase, propofol, tamoxifen |
Class III drug | At least two case reports but do not have re-challenge data or a consistent latency period | Alendronate, carbamazepine, ceftriaxone, clarithromycin, cyclosporin, hydrochlorothiazide, interferone/ribavirin, metformin, minocycline, naproxen, paclitaxel, prednisone, prednisolone |
Class IV drug | One case report without re-challenge data | Ampicillin, cisplatin, colchicine, cyclophosphamide, diclofenac, doxorubicin, interleukin-2, octreotide, propoxyphene, rifampin, risperidone, sertaline, tacrolimus, vincristine |
Mechanism of DIAP | Drugs with a definite relationship or with classI/II to AP | Probable | Similar structure/class/mechanism withreported cases |
Structural | Cholestatic liver injury | Rofecoxib | |
Azathioprine | |||
Cytarabine | |||
Spasm of the sphincter of Oddi | Octreotide | Opium | |
Opioids | Marcolides | ||
Codeine | |||
Erythromycin | |||
Obstruction | ACE-inhibitors | ||
Enalapril-angioedema | |||
Duct constriction | NSAIDs | ||
Sulindac | |||
Stone | Ceftriaxone | ||
Dipyridamole | |||
Toxins | Acetaminophen | Metformin | Minocycline |
Didanosine | Tigecycline | ||
Isoniazid | Doxycycline | ||
Metronidazole | NRTI | ||
Valproic acid | HMG-CoA reductase inhibitors | ||
Mesalamine | |||
Pentamidine | |||
Asparaginase | |||
Sitaliptin | |||
Exenatide | |||
Tetracycline | |||
Pravastatin | |||
Metabolic | Hypertriglyceridemia | Hydrochlorothiazide | Isotretinoin |
Estrogens | Interferon alfa | Retinoid derivaties | |
Corticosteroids | Propofol | Protease inhibitors | |
Furosemide | Tamoxifen | Saw palmetto | |
β-blocker | Ethacrynic acid | ||
Clomiphene | Anti-psychotics (aripiprazole, clozapine, olanzapine, quetiapine, risperidone) | ||
Hypercalcemia | IV calcium | ||
Vitamin D | |||
Vascular | Contrast media - iopamidol Procainamide | ||
Immune-mediated | Azathioprine/mercaptopurine sulfasalazine |
- Citation: Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol 2014; 5(4): 405-415
- URL: https://www.wjgnet.com/2150-5330/full/v5/i4/405.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v5.i4.405